Nama's AI scorecard currently rates Xencor Sell (3.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does XNCR report earnings?

Xencor's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.79.

What is the XNCR price target?

The median analyst price target from 12 analysts is $42.00, with a range of $21.00 – $70.00.

Is XNCR Shariah compliant?

Nama's AAOIFI-style screen reads Xencor as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Xencor (XNCR)

Healthcare · Biotechnology · NASDAQ

Xencor (XNCR) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.68B and a free-cash-flow yield of -5.2%. Over the most recent reported fiscal year, revenue grew 13.7%. Nama's AI scorecard rates it Sell, 3.3 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 3.3/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Rising · +73.3% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-15.5%

How far the last close sits under the highest price of the past five years.

Market cap	$2.68B
Trailing P/E	—
Price / book	5.3
Price / sales	25.4
FCF yield	-5.2%
Dividend yield	—
Gross margin	-143.7%
Operating margin	—
Net margin	-155.6%
Revenue growth (YoY)	+13.7%
Revenue growth (3-yr annual)	-8.6%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

XNCR earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate -$0.79). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.50	-$0.34	+247.1%	$116.52M
Q2 2026	Aug 5, 2026	-$0.29	-$0.84	+65.5%	$51.22M
Q1 2026	May 6, 2026	-$1.71	-$0.75	-128.0%	$4.52M
Q4 2025	Feb 25, 2026	-$0.09	-$0.58	+84.5%	$28.24M

XNCR analyst price target

Median target $42.00 from 12 analysts, ranging $21.00 – $70.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live XNCR data on Nama Insights →

XNCR FAQ

Is XNCR a buy?: Nama's AI scorecard currently rates Xencor Sell (3.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does XNCR report earnings?: Xencor's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.79.
What is the XNCR price target?: The median analyst price target from 12 analysts is $42.00, with a range of $21.00 – $70.00.
Is XNCR Shariah compliant?: Nama's AAOIFI-style screen reads Xencor as Not Shariah Compliant. At least one of the three ratios or the industry test failed.